tradingkey.logo

Caris Life Sciences Inc

CAI
查看詳細走勢圖
30.380USD
-0.800-2.57%
收盤 11/04, 16:00美東報價延遲15分鐘
8.54B總市值
虧損本益比TTM

Caris Life Sciences Inc

30.380
-0.800-2.57%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-2.57%

5天

0.00%

1月

-4.41%

6月

0.00%

今年開始到現在

0.00%

1年

0.00%

查看詳細走勢圖

TradingKey Caris Life Sciences Inc股票評分

單位: USD 更新時間: 2025-11-04

操作建議

目前公司基本面數據相對非常健康,公司估值合理,機構認同度非常高,近一個月多位分析師給出公司評級為強力買入。公司市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Caris Life Sciences Inc評分

相關信息

行業排名
83 / 210
全市場排名
184 / 4616
所屬行業
醫療設備與耗材

壓力支撐

暫無數據

多維評測

本期評分
上期評分

分析師目標

基於 8 分析師
強力買入
評級
39.125
目標均價
+30.68%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Caris Life Sciences Inc亮點

亮點風險
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
估值合理
公司最新PE估值0.00,處於3年歷史合理位
機構加倉
最新機構持股130.22M股,環比增加49.73%
菲利普·拉豐持倉
明星投資者菲利普·拉豐持倉,最新持倉10.14M股

Caris Life Sciences Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

暫無數據

營業總收入

暫無數據

Caris Life Sciences Inc簡介

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代碼CAI
公司Caris Life Sciences Inc
CEOMr. David Dean Halbert
網址https://www.carislifesciences.com/
KeyAI